REGENXBIO Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
REGENXBIO Inc. (RGNX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$193.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-05
- REGENXBIO Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$193.79M.
- REGENXBIO Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$227.02M.
- REGENXBIO Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$263.57M.
- REGENXBIO Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$280.34M, a 298.40% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$193.79M 10-K · filed 2026-03-05 |
| 2024-12-31 | -$227.02M 10-K · filed 2026-03-05 |
| 2023-12-31 | -$263.57M 10-K · filed 2025-03-13 |
| 2022-12-31 | -$280.34M 10-K · filed 2025-03-13 |
| 2021-12-31 | $141.30M 10-K · filed 2024-02-27 |
| 2020-12-31 | -$105.96M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$97.44M 10-K · filed 2022-03-01 |
| 2018-12-31 | $104.18M 10-K · filed 2021-03-01 |
| 2017-12-31 | -$73.14M 10-K · filed 2020-02-26 |
| 2016-12-31 | -$63.40M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |